Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 5/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744735 | 0.86 | KDM4E (0.48) | ACMSDMCL1ALOX5CYP2D6CYP2C9 | |
| SCHEMBL745519 | 0.84 | ACMSD (0.49) | ACMSDMCL1XDHSLC22A12CYP1A2 | |
| SCHEMBL27542885 | 0.78 | ACMSD (0.62) | ACMSDMCL1CYP1A2CYP2C19SOS1 | |
| SCHEMBL1247836 | 0.74 | ACMSD (0.63) | ACMSDMCL1XDHSLC22A12LCK | |
| SCHEMBL12892157 | 0.73 | MCL1 (0.74) | ACMSDMCL1XDHSLC22A12GRIN2D | |
| SCHEMBL19688783 | 0.72 | NR4A1 (0.56) | ACMSDMCL1SOS1HSD17B10LDHA | |
| SCHEMBL3368675 | 0.72 | ALDH1A1 (0.62) | ACMSDCYP1A2CYP2C19SOS1HIF1A | |
| SCHEMBL29618929 | 0.72 | SLC6A2 (0.66) | ACMSDMCL1CYP1A2CYP2C19SOS1 | |
| SCHEMBL84188 | 0.72 | SLC6A2 (0.66) | ACMSDMCL1CYP1A2CYP2C19SOS1 | |
| SCHEMBL30610922 | 0.72 | SLC6A2 (0.66) | ACMSDMCL1CYP1A2CYP2C19SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | BPGBIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-2983654-B1 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGBIO INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | BPGBIO, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | BPGBIO, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | BERG LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BERG, KARA ANN | 2022-06-30 | — | — | US | disclosed |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | BERG LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | THLIVERIS, ANDREW T. | 2022-03-31 | — | — | US | disclosed |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG PHARMA LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2011031503-A2 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2010132440-A2 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132479-A2 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132502-A2 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132507-A2 | METHODS FOR TREATMENT OF DISEASE USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | SLC25A20, NDUFB10, NDUFA10 | ACMSD 4565/4885MCL1 727/4885XDH 702/4885 |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | VEGFA, NDUFA10, NDUFB10 | ACMSD 4497/4885MCL1 1270/4885XDH 1868/4885 |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | ACMSD 4450/4885MCL1 1458/4885XDH 1020/4885 |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | NDUFA10, NDUFB10, NDUFA5 | ACMSD 3675/4885MCL1 635/4885XDH 1414/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | ACMSD 3722/4885MCL1 1587/4885XDH 1397/4885 |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | PC, GLS2, PCK2 | ACMSD 3506/4885MCL1 2687/4885XDH 1442/4885 |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | ACMSD 4565/4885MCL1 727/4885XDH 702/4885 |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | NDUFB10, NDUFA10, COQ8A | ACMSD 3220/4885MCL1 2402/4885XDH 898/4885 |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | NDUFB10, NDUFA10, NDUFB5 | ACMSD 4450/4885MCL1 1458/4885XDH 1020/4885 |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | ACMSD 4608/4885MCL1 577/4885XDH 984/4885 |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | NDUFB10, SDHB, SDHA | ACMSD 3939/4885MCL1 1248/4885XDH 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.